Trial Profile
A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Sponsors Anterogen
- 23 Aug 2023 Planned End Date changed from 30 Dec 2022 to 1 May 2024.
- 23 Aug 2023 Planned primary completion date changed from 30 Dec 2022 to 1 Nov 2023.
- 23 Aug 2023 Status changed from recruiting to active, no longer recruiting.